The Court of Appeal in Paris has ruled that Sanofi must pay 150.7 million euros to CNAM as compensation for anti-competitive practices related to the drug Plavix.
Matei Gaginsky
International
Foto: Sylvain ROBIN / Alamy / Profimedia
Always see our news on Google
The court's decision is based on a ruling from 2013, when Sanofi was fined 40.6 million euros for actions against generic drug manufacturers. The court found that the impact of these practices persisted until 2021, although the anti-competitive behavior lasted only five months. CNAM will receive 126.2 million euros for reimbursements and fees, plus 24.5 million euros in damages. Sanofi is reviewing the ruling and considers the possibility of an appeal to the Supreme Court.
Sources
Latest News
07:23
Sorin Grindeanu returns Ilie Bolojan’s offer / PSD votes for a minority PNL-UDMR government. Come on!
07:16
Kelemen Hunor estimates that Luca Niculescu has an 80% chance of securing the government’s investiture in Parliament
22:57
Prosecutor seeks sentences of up to 12 years for three doctors accused in the death of Diego Maradona
22:53
Donald Trump calls those who use the term “artificial intelligence” instead of “Super Intelligence” “enemies”
22:42
A bison weighing over 800 kilograms was found dead and decapitated in Măgura Ilvei. The police are investigating the case
See more news
NEWS ON THE SAME TOPICS
International
Germany will provide €400 million to maintain Sanofi’s insulin production and reduce the risk of shortages in Europe
International
Poland contests the ruling of the Brussels Tribunal to pay 1.3 billion euros for the Pfizer vaccines
Current Affairs
Fine of 9.91 million lei for Albalact. The court definitively ruled in favor of the Competition Council
Current Affairs
Philips Romania was fined 5.18 million lei after an employee uninstalled WhatsApp during an inspection
Personalized news feed, AI-powered search, and notifications in a more interactive experience.
